Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer

Autor: Parkes, Eileen E., Savage, Kienan I., Lioe, Tong, Boyd, Clinton, Halliday, Sophia, Walker, Steven M., Lowry, Keith, Knight, Laura, Buckley, Niamh E., Grogan, Andrena, Logan, Gemma E., Clayton, Alison, Hurwitz, Jane, Kirk, Stephen J., Xu, Jiamei, Sidi, Fatima Abdullahi, Humphries, Matthew P., Bingham, Victoria, Ang, Melvyn, Askin, Conal, Bamford, Louise, Boyd, Ruth, Buckley, Miriam, Clarke, Jacqueline, Darragh, Lynn, Davis, Elaine, Foreman, Jennifer, Gallagher, Rebecca, Gill, Janine, Hanna, Michael, Hill, Naomi, Irwin, Gareth, Mallon, Peter, McAleer, Seamus, McAllister, Joanne, Morris, Melanie, Pierce, Nicole, Refsum, Sigi, Sloan, Samantha, Treanor, Sinead, James, Jacqueline, James, Colin R., Paul Harkin, D., Kennedy, Richard D., McIntosh, Stuart A.

Publikováno v: Parkes, E E, Savage, K I, Lioe, T, Boyd, C, Halliday, S, Walker, S M, Lowry, K, Knight, L, Buckley, N E, Grogan, A, Logan, G E, Clayton, A, Hurwitz, J, Kirk, S J, Xu, J, Sidi, F A, Humphries, M P, Bingham, V, Ang, M, Askin, C, Bamford, L, Boyd, R, Buckley, M, Clarke, J, Darragh, L, Davis, E, Foreman, J, Gallagher, R, Gill, J, Hanna, M, Hill, N, Irwin, G, Mallon, P, McAleer, S, McAllister, J, Morris, M, Pierce, N, Refsum, S, Sloan, S, Treanor, S, James, J, James, C R, Paul Harkin, D, Kennedy, R D & McIntosh, S A 2022, ' Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer ', British Journal of Cancer, vol. 126, no. 2, pp. 247-258 . https://doi.org/10.1038/s41416-021-01599-0
British Journal of Cancer

Background The DNA-damage immune-response (DDIR) signature is an immune-driven gene expression signature retrospectively validated as predicting response to anthracycline-based therapy. This feasibility study prospectively evaluates the use of this a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89093693d780af5cb3b489f2e8467878
https://pure.qub.ac.uk/en/publications/ddcf60ae-b538-40b3-8534-1226cc8804ab

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.

Autor: McGivern N; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK., El-Helali A; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK., Mullan P; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK., McNeish IA; Institute of Cancer Sciences, University of Glasgow, Scotland, UK., Paul Harkin D; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK.; Almac Diagnostics, 19 Seagoe Industrial Estate, Craigavon, Northern Ireland, UK., Kennedy RD; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK.; Almac Diagnostics, 19 Seagoe Industrial Estate, Craigavon, Northern Ireland, UK., McCabe N; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK.; Almac Diagnostics, 19 Seagoe Industrial Estate, Craigavon, Northern Ireland, UK.

Publikováno v: Oncotarget [Oncotarget] 2017 Dec 20; Vol. 9 (4), pp. 4722-4736. Date of Electronic Publication: 2017 Dec 20 (Print Publication: 2018).